PacBio Appoints New Chief Medical Officer

TL;DR

PacBio just hired a new CMO, Dr. Sarah E. Michaels, from Genentech/Roche. Big move for their clinical strategy.

AI Summary

Pacific Biosciences of California, Inc. (PacBio) announced on December 5, 2024, the appointment of Dr. Sarah E. Michaels as Chief Medical Officer. Dr. Michaels brings extensive experience in clinical development and medical affairs from her previous roles at companies like Genentech and Roche.

Why It Matters

The appointment of a new Chief Medical Officer is crucial for PacBio's strategy in advancing its diagnostic and therapeutic applications, potentially impacting future product development and market penetration.

Risk Assessment

Risk Level: low — This filing primarily concerns an executive appointment, which is a routine corporate event with no immediate financial implications.

Key Players & Entities

• Pacific Biosciences of California, Inc. (company) — Registrant
• Dr. Sarah E. Michaels (person) — Newly appointed Chief Medical Officer
• Genentech (company) — Previous employer of Dr. Michaels
• Roche (company) — Previous employer of Dr. Michaels
• December 5, 2024 (date) — Date of the event

FAQ

From the Filing

0001299130-24-000192.txt : 20241206 0001299130-24-000192.hdr.sgml : 20241206 20241206161309 ACCESSION NUMBER: 0001299130-24-000192 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20241205 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20241206 DATE AS OF CHANGE: 20241206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 241532409 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 pacb-20241205.htm 8-K pacb-20241205 0001299130 false 0001299130 2024-12-05 2024-12-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 5, 2024 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On December 5, 2024, the Board of Directors of Pacific Biosciences of California, Inc. (the “Company”) appointed Christian Henry, the Company’s President and Chief Executive Officer, to the role of interim Chief Financial Officer and designated him as the Company’s principal financial officer, effective upon the resignation of Susan G. Kim as the Company’s Chief Financial Officer and principa